**Core tip:** Azathioprine (AZA) plays an important role in the remission maintenance therapy of inflammatory bowel disease (IBD). However, serious drug adverse reactions, especially leukopenia, limit its clinical application. European consensus has identified *TPMT* polymorphism as a predictor of AZA-induced leukopenia. However, the predictive value of *TPMT* is controversial in Asians with low mutation rate and effectiveness. *NUDT15* polymorphism has recently been found to be strongly associated with AZA-induced leukopenia in Asians but there are few data in Chinese populations. This study aimed to observe *TPMT* and *NUDT15* polymorphisms and compare their predictive value for AZA-induced leukopenia in Chinese IBD patients.

INTRODUCTION
============

Inflammatory bowel disease (IBD) is a chronic nonspecific intestinal inflammatory disease\[[@B1]\]. The pathogenesis of IBD is still unknown but is possibly related to genetic and environmental factors, as well as intestinal immune dysfunction. IBD mainly includes ulcerative colitis (UC), Crohn's disease (CD) and unclassified IBD (UIBD). During the 21^st^ century, IBD has become a global disease with accelerating incidence in the newly industrialized countries, including Asia, and has caused a huge social and economic burden. An epidemiological study among the ACCESS countries showed an incidence of IBD in China of 3.3 cases per 100000 population, with an increasing trend\[[@B2]\].

The main goal of IBD treatment is to induce and maintain remission and prevent complications\[[@B3]\]. Treatment strategies of IBD include 5-aminosalicylate compounds, steroids, immune modulators and biological agents. Patients with IBD need long-term treatment to maintain remission due to its lifelong relapsing-remitting tendency. Immune modulators, especially azathioprine (AZA), have played an important role in maintaining remission. However, the adverse reactions of AZA, especially leukopenia, seriously limit its clinical application\[[@B4]\]. Research on the metabolic enzymes and adverse reactions of AZA has become popular and controversial. What is the value of these enzymes? How do they influence adverse reactions of AZA?

Thiopurine S-methyltransferase (TPMT), an enzyme of AZA metabolism, has been reported as a risk predictor for AZA-induced leukopenia in Caucasians. The United States Food and Drug Administration has proposed that TPMT status should be assessed before AZA therapy\[[@B5]\]. Researchers\[[@B6]\] have pointed out that AZA should not be used if TPMT activity is deficient because of a high risk of AZA-induced leukopenia. AZA should be used at a lower dose to reduce adverse reactions if TPMT activity is intermediate. However, AZA-induced leukopenia still occurs in patients with normal activity of TPMT. Moreover, although the mutation rate of *TPMT* is lower in Asians (1%-3%) than that in Caucasians (about 10%), the incidence of AZA-induced leukopenia in Asians (about 35.4%) is higher than that in Caucasians (about 5%)\[[@B7]\]. Thus, the predictive value of *TPMT* polymorphism for AZA-induced leukopenia is uncertain, especially among Asian populations.

Recent studies have revealed that *NUDT15* polymorphism is a better predictor for drug adverse reactions with a higher mutation rate in Asians than *TPMT*\[[@B8]\]. However, little research has been done on the correlation between *NUDT15* polymorphism and AZA-induced leukopenia in Chinese populations. Therefore, our study aimed to observe the gene polymorphism frequency distributions of *TPMT* and *NUDT15*, and compare their value in predicting AZA-induced leukopenia in patients with IBD to help optimize AZA therapy for IBD.

MATERIALS AND METHODS
=====================

Patients
--------

We enrolled 219 patients with IBD (160 men and 59 women), including 39 cases of UC, 176 of CD and 4 of UIBD. All of the patients visited Xiangya Hospital, Central South University (Changsha, China) from February 2016 to November 2017. Study inclusion criteria were: (1) diagnosis and disease activity based on the Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2012, Guangzhou)\[[@B9]\]; (2) age 16-80 years; and (3) written informed consent obtained before examination. Exclusion criteria were: (1) severe cardiac, hepatic and/or renal insufficiency; (2) mucous biopsy diagnosed as carcinoma or lymphoma; (3) active tuberculosis; (4) active viral hepatitis with an obvious increase in transaminase (\> 2 times the upper limit of normal), and/or hepatitis B e antigen(+) with hepatitis B virus DNA \> 10^5^ copies/mL or hepatitis B e antibody(+) with hepatitis B virus DNA \> 10^4^ copies/mL; (5) comorbidity such as bacterial or viral infection that had not been controlled effectively; and (6) acute abdominal disease, or other surgical indications (such as complicated fistula and intestinal obstruction caused by fibrosis).

Genotyping
----------

Peripheral blood samples (2-3 mL) were obtained from enrolled patients and total genomic DNA was extracted from peripheral leukocytes. The variants in the *NUDT15* gene of *R139C* (c.415C\>T, rs116855232) and the *TPMT* variants of *TPMT\*3C* (p.Tyr240Cys, c.719A\>G, rs1142345) were genotyped at the Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University. Genotyping was performed using pyrosequencing and the results were validated by Sanger sequencing. Pyrosequencing and Sanger sequencing primers were designed with PyroMark Assay Design software 2.0 (Qiagen, Hilden, Germany) and PrimerQuest Tool (IDT, San Jose, CA, United States), respectively. The sequences of the forward, reverse and sequencing primers for rs116855232 were 5'-GTGGGTTCCTTGGGAAGAACTA-3', 5'-ATCCCACCAGATGGTTCAGATCTT-3' and 5'-GCTTTTCTGGGGACTG-3', respectively. The sequences of the forward, reverse and sequencing primers for rs1142345 were 5'-TGGGGAATTGACTGTCTTTTTGA-3', 5'-TCCATTACATTTTCAGGCTTTAGC-3' and 5'-GACTGTCTTTTTGAAAAGTT-3', respectively. Conditions for polymerase chain reaction were 35 cycles of 30 s at 95 °C for denaturation, 30 s at 57 °C for annealing and 30 s at 72 °C for extension.

AZA treatment
-------------

Initial dose of AZA was 0.5-1.5 mg/kg daily, based on the Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2012, Guangzhou)\[[@B9]\]. Patients who used AZA underwent routine blood tests every week during the first month, then every 2 wk for 2 mo, followed by every month, as well as liver function tests every month. If patients had no adverse reactions, then AZA dose was increased by 0.5 mg/kg daily every month to 1.0-2.0 mg/kg/d. If AZA was effective without adverse reactions, patients should take it for life. If patients developed leukopenia (white blood cell count \< 3.5 × 10^9^/L or neutrophils \< 1.5 × 10^9^/L) and/or other severe adverse reactions, such as leukopenia, hepatoxicity, severe gastrointestinal adverse reactions and/or severe hair loss, the treatment was discontinued. The workflow of the study is shown in Figure [1](#F1){ref-type="fig"}.

![Study design. ^1^Adverse reactions included leukopenia (white blood cell count \< 3.5 × 10^9^/L or neutrophils \< 1.5 × 10^9^/L), hepatoxicity, severe gastrointestinal adverse reactions and severe hair loss; ^2^Drug dose was increased by 0.5 mg/kg daily every month gradually to 1.0-2.0 mg/kg daily. AZA: Azathioprine; IBD: Inflammatory bowel disease.](WJG-24-941-g001){#F1}

Ethics
------

The study was approved by the ethics committee of the hospital, and written informed consent was obtained before examination.

Statistical analysis
--------------------

Data such as baseline characteristics including age, sex, disease stage, initial dose and duration of AZA were compared using the χ^2^ or Student's *t* test. Combined use of other drugs and the frequency of leukopenia for each genotype were compared by analysis of χ^2^ tests. Logistic regression analyses were also performed to identify the associations of leukopenia with each genotype and other factors in multivariate analyses. To study the implication of different genes (*NUDT15* and *TPMT*) in AZA-mediate leukopenia, we calculated relative risk (RR), etiological fraction (EF; if RR \> 1) and preventive fraction (PF; if RR \< 1). *P* \< 0.05 was considered significant. All analyses were performed using SPSS version 18 (SPSS Inc., Chicago, IL, United States).

RESULTS
=======

Mutation rate of NUDT15 was higher than that of TPMT
----------------------------------------------------

A total of 219 patients (UC 39, CD 176 and UIBD 4) participated in this study and 80 of them received AZA therapy. All patients were checked for their genotypes of *NUDT15 R139C* and *TPMT \*3C*. The baseline characteristics of the patients are summarized in Table [1](#T1){ref-type="table"}. More men than women received AZA treatment. Mutation rate of *TPMT* (1.4%) was significantly lower than that of *NUDT15* (20.1%) (*P* = 0.000), which was in accordance with other studies (Figure [2](#F2){ref-type="fig"}).

###### 

Characteristics of patients

                                        UC              CD              UIBD            Total
  ------------------------------------- --------------- --------------- --------------- ---------------
  No. of patients (*n*)                 39 (17.8)       176 (80.4)      4 (1.8)         219
  Age in yr                             42.74 ± 13.60   30.51 ± 11.84   45.25 ± 16.62   33.44 ± 13.08
  Sex, M/F                              27/12           132/44          1/3             161/59
  *TPMT* genotype                                                                       
  A/A                                   38 (97.4)       174 (98.9)      4 (100)         216 (98.6)
  A/G[a](#T1FN1){ref-type="table-fn"}   1 (2.6)         2 (1.1)         0               3 (1.4)
  *NUDT15* genotype                                                                     
  C/C                                   31 (79.5)       140 (79.5)      4 (100)         175 (79.9)
  C/T                                   8 (20.5)        36 (20.5)       0               44 (20.1)
  AZA therapy                           3 (7.7)         77 (43.8)       0               80 (36.5)

Data are presented as *n* (%) or mean ± SD.

*P* \< 0.05 *vs NUDT15 C/T*. CD: Crohn's disease; UC: Ulcerative colitis; UIBD: Undetermined inflammatory bowel disease, AZA: Azathioprine.

![Gene polymorphism frequency distributions of *TPMT* and *NUDT15*. ^a^*P* \< 0.05 *vs* mutant type of *TPMT* group.](WJG-24-941-g002){#F2}

Leukopenia was significantly associated with NUDT15 R139C
---------------------------------------------------------

Patients characteristics, AZA initial dose, AZA duration, disease stage, adverse events and genotype of *NUDT15* are summarized in Table [2](#T2){ref-type="table"}. Sixty-four patients with *NUDT15* C/C (80.0%) and 16 with C/T (20.0%) received AZA therapy. There were no significant differences in the age, sex, disease stage, initial dose of AZA, duration of AZA and combined treatment between these two groups. Eight of 16 patients with *NUDT15* C/T developed leukopenia after receiving AZA therapy, while only 11/64 (11.7%) patients with *NUDT15* C/C had leukopenia; there was a significant difference between the two groups (*P* = 0.006) (Figure [3A](#F3){ref-type="fig"}). Thus, patients with *NUDT15* C/T had a higher risk of AZA-induced leukopenia than those with *NUDT15* C/C.

###### 

Association analysis of azathioprine and *NUDT15* polymorphism

  Genotype of ***NUDT15***               C/C             C/T                                        Total           *P* value
  -------------------------------------- --------------- ------------------------------------------ --------------- -----------
  No. of patients (gene frequencies)     64 (90.0)       16 (10.0)                                  80              \-
  Age in yr                              33.69 ± 11.31   31.13 ± 12.40                              33.18 ± 11.50   0.429
  Sex, M/F                               48/16           11/5                                       59/21           0.611
  Disease stages                                                                                                    
  Remission                              6 (9.4)         3 (18.8)                                   9 (11.3)        0.253
  Mild activity                          10 (15.6)       2 (12.5)                                   12 (15.0)       
  Moderate activity                      35 (54.7)       5 (31.3)                                   40 (50.0)       
  Severe activity                        13 (20.3)       6 (37.5)                                   19 (23.8)       
  Initial dosage of AZA in mg/kg daily   1.044 ± 0.318   1.241 ± 0.252                              1.082 ± 0.441   0.596
  Duration of AZA in mo                  8.1 ± 11.19     9.3 ± 9.95                                 8.4 ± 10.90     0.686
  Combined with corticosteroids          28 (43.8)       5 (31.3)                                   33 (41.3)       0.071
  Combined with IFX                      14 (21.9)       7 (43.8)                                   21 (26.3)       
  Combined with IFX and corticosteroid   0               1 (6.3)                                    1 (1.3)         
  Leukopenia                             11 (17.2)       8 (50.0)[a](#T2FN1){ref-type="table-fn"}   19 (23.8)       0.006

Data are presented as *n* (%) or mean ± SD.

*P* \< 0.05 *vs NUDT15 C/C* developed leukopenia. AZA: Azathioprine; IFX: Infliximab.

![Occurrence of leukopenia with different genotypes of *NUDT15* (A) and *TPMT* (B). ^a^*P* \< 0.05 *vs NUDT15 C/C* developed leukopenia group.](WJG-24-941-g003){#F3}

We also analyzed *TPMT* gene polymorphism. Most patients (98.75%) were homozygous for the wild allele of *TPMT* (A/A) and 18 (22.8%) developed leukopenia after using AZA, while only 1 patient showed heterozygous *TPMT* (A/G) and then developed leukopenia, with no significant differences between the *TPMT* polymorphism and incidence of leukopenia (*P* = 0.071) (Figure [3B](#F3){ref-type="fig"}). Based on these results, we suggest that *TPMT* polymorphism does not predict AZA-induced leukopenia efficiently.

AZA-induced leukopenia negatively correlated with corticosteroid usage and female sex
-------------------------------------------------------------------------------------

In the logistic regression analysis with age, sex, combined drug use, disease stage, *TPMT* risk allele counts and *NUDT15* risk allele counts, we found that *NUDT15* polymorphism was significantly associated with AZA-induced leukopenia (*P* = 0.004, OR = 7.663, 95%CI: 1.893-31.023, RR = 2.909, EF = 0.276). In addition, we found that the incidence of AZA-induced leukopenia negatively correlated with corticosteroid usage and female sex (Table [3](#T3){ref-type="table"}). Fewer women than men developed leukopenia after receiving AZA (*P* = 0.039, odds ratio (OR) = 0.146, 95% confidence interval (CI): 0.023-0.909, RR = 0.527, PF = 0.124). Combination with glucocorticoids reduced the risk of AZA-induced leukopenia (*P* = 0.023, OR = 0.201, 95%CI: 0.050-0.798, RR = 0.437, PF = 0.253). We found that age, disease stage, duration of AZA and combination with other drugs were not significantly associated with AZA-induced leukopenia, except for corticosteroids.

###### 

Multivariate association analyses of azathioprine-induced leukopenia

  Factor                                 *P* value   OR (95%CI)             RR      EF/PF
  -------------------------------------- ----------- ---------------------- ------- -------
  Age                                    0.714       \-                     \-      \-
  Sex, female                            0.039       0.146 (0.023-0.909)    0.527   0.124
  Disease stages                         0.509       \-                             \-
  Duration of AZA                        0.438       \-                             \-
  Combined with corticosteroids          0.023       0.201 (0.050-0.798)    0.437   0.253
  Combined with IFX                      0.339       \-                     \-      \-
  Combined with IFX and corticosteroid   1.000       \-                     \-      \-
  *TPMT*                                 1.000       \-                     \-      \-
  *NUDT15*                               0.004       7.663 (1.893-31.023)   2.909   0.276

DISCUSSION
==========

AZA is an antimetabolic immunosupressor that plays a key role in remission maintenance treatment of IBD. It can be used in patients who are dependent on corticosteroids or in whom corticosteroids are ineffective, as well as in those with fistulas or operations\[[@B10]\]. AZA is metabolized by multiple enzymes through three main pathways\[[@B11]\]. (1) Steps depending on hypoxanthine phosphoribosyl transferase, inosine monophosphate dehydrogenase and GMP synthetase and eventually transferred into 6-thioguanosine triphosphate (6-TGTP). 6-TGTP is an effective form of AZA that is incorporated into double-strand DNA to inhibit its synthesis and trigger apoptosis, as well as causing bone marrow toxicity\[[@B12]\]; (2) Oxidization by xanthine oxidase and conversion into 6-thiouric acid, an inactive product of AZA; and (3) Catalysis by TPMT and conversion into 6-methylmercaptopurine. These three pathways are mutually competitive.

Although AZA is cost-effective, adverse reactions such as leukopenia may lead to severe and life-threatening infections that result in treatment discontinuation. A study by Kakuta et al\[[@B13]\] showed that 34 (25.2%) of 135 Japanese patients with IBD developed leukopenia after receiving AZA therapy. Yang et al\[[@B8]\] found that 346 (35.4%) of 978 Korean patients with CD developed AZA-induced leukopenia. Consistent with these results, we found that 19 (23.8%) of 80 Chinese patients with IBD discontinued AZA treatment due to leukopenia. So, the incidence of AZA-induced leukopenia is high in Asians and should not be ignored. Research on AZA has found that *TPMT* polymorphism is significantly associated with AZA-induced leukopenia, and \> 40 different variant *TPMT* alleles (*TPMT\*2-\*41*) have been studied\[[@B14],[@B15]\]. Among them, *TPMT\*3C* is the most popular variant in Asians, but the gene frequency is low (1%-3%)\[[@B16]\]. Gazouli et al\[[@B17]\] have found no association between *TPMT* polymorphisms and the occurrence of AZA-related adverse events. In our study, the variation of *TPMT* (1.4%) was rare and not significantly associated with AZA-induced leukopenia in Chinese patients with IBD, which was consistent with previous reports. Thus, the predictive value of *TPMT* polymorphism is controversial in Asians.

*NUDT15* also known as MTH2, is a member of the Nudix hydrolytic enzyme family, which degrades 8-o-dGTP into 8-o-dGMP and prevents DNA from mismatch. Carter et al\[[@B18]\] have revealed that *NUDT15* has a strong effect on dGTP, 6-TGTP and dUTP. It hydrolyzes 6-TGTP into 6-TGMP, decreases the level of AZA active metabolites and prevents AZA-induced leukopenia. Yang et al\[[@B8]\] have reported that *NUDT15* polymorphism is strongly associated with thiopurine-induced early leukopenia in Koreans. Zhu et al\[[@B19]\] have found in Chinese patients that *NUDT15* has a high mutation rate (22.5%) that is strongly associated with the incidence of AZA-induced leukopenia. A study of Singapore patients with IBD\[[@B20]\] has also revealed that patients with low and intermediate NUDT15 activity have significantly higher risks of developing AZA-induced leukopenia. We verified the same conclusion that the incidence of an aberrant *NUDT15* was 10.0% significantly higher than that of *TPMT* (*P* = 0.000) and *NUDT15* could be an important pharmacogenetic marker for predicting AZA-induced leukopenia in a Chinese cohort (*P* = 0.004, OR = 7.663, 95%CI: 1.893-31.023, RR = 2.909, EF = 0.276).

This is a prospective study that has a lot of clinical value. Our results were significant to optimize AZA therapy for Chinese patients with IBD and helpful to provide more data in Chinese populations and to further multicenter large-scale research. Moreover, we are the first to describe that combined use of corticosteroids is a negative factor for developing AZA-induced leukopenia. Patients who received corticosteroids along with AZA treatment, or those with corticosteroid-induced remission and maintenance by AZA had a lower risk of developing leukopenia (*P* = 0.023, OR = 0.201, 95%CI: 0.050-0.798, RR = 0.437, PF = 0.253). This may be explained by the function of corticosteroids\[[@B22]\] in enhancing bone marrow hematopoiesis and promoting neutrophil release and increasing the number of circulating neutrophils, as well as reducing the infiltration and consumption of neutrophils in the inflammatory regions.

In contrast to the study by Kakuta et al\[[@B13]\], which showed that sex was not associated with AZA-induced leukopenia, we found that women were less likely to develop leukopenia after receiving AZA than men (*P* = 0.039, OR = 0.146, 95%CI: 0.023-0.909, RR = 0.527, PF = 0.124). The exact mechanism was unknown. We supposed that might be related to sex differences in pharmacokinetics. More specifically, females may have a lower apparent volume of distributions than males because of the solubility of the drug so that AZA might be removed more quickly in females, which reduces the risk of AZA-induced leukopenia. However, since more men received AZA treatment than women in our study, further study is needed to confirm the relationship between sex and AZA-induced leukopenia.

Our study had a few limitations, including that no patients with *NUDT15*(T/T) participated in our study. Recent studies have detected additional variants of *NUDT15*, except *R139C*, including Arg139His, Val18Ile and p.Val18_Val19insGlyVal, and defined six haplotype (\*1 to \*6) combinations of these variants\[[@B21]\], but we have not investigated these in the present study. So, further multicenter studies with larger sample size are warranted in this area.

In conclusion, the mutation rate of *NUDT15* in Chinese patients with IBD is significantly higher than that of *TPMT*. *NUDT15* polymorphism is a better predictor for AZA-induced leukopenia than *TPMT* polymorphism. Combined use of corticosteroids is a potential way to reduce the risk of AZA-induced leukopenia. Males have a higher risk of developing AZA-induced leukopenia and need to be more closely monitored than females. Further research is necessary to verify this relationship and determine the precise mechanism.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Azathioprine (AZA) plays a key role in remission maintenance therapy of inflammatory bowel disease (IBD), although it causes serious adverse reactions, including leukopenia. *TPMT* polymorphism is a predictor of AZA-induced leukopenia in Caucasians. However, the predictive value of *TPMT* is controversial in Asians. *NUDT15* polymorphism is a more effective predictor of AZA-induced leukopenia in Asians, but there are few data in Chinese populations.

Research motivation
-------------------

The purpose of this study was to observe *TPMT* and *NUDT15* polymorphisms and compare their values in predicting AZA-induced leukopenia in Chinese IBD patients.

Research objectives
-------------------

To find a more valuable predictor of AZA-induced leukopenia in Chinese patients with IBD, improve our ability to manage these patients more safely, and optimize AZA therapy.

Research methods
----------------

A total of 219 patients diagnosed with IBD in Xiangya Hospital, Central South University were enrolled. Peripheral blood of all patients was collected to detect their genotypes of *TPMT* and *NUDT15* by pyrosequencing at the Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital. Eighty patients were treated with AZA according to the disease condition. Patients who received AZA underwent routine blood tests and liver function tests once a week. Data analysis was performed by *χ*^2^ test, Student's *t* test or logistic regression analyses using SPSS version 18.

Research results
----------------

We enrolled 219 patients with IBD (160 men and 59 women). There were 44 patients (20.1%) with mutant genotype of *NUDT15* (C/T); among them, 16 received AZA, and 8 (50%) developed leukopenia. There were 175 patients (79.7%) with wild genotype of *NUDT15* (C/C); among them, 64 received AZA, and 11 (17.2%) developed leukopenia. A significant difference was found between *NUDT15* C/T and its wild-type C/C (*P* = 0.004). There were only 3 patients with *TPMT* mutant genotype of A/G (1.4%) and 1 was treated with AZA and then developed leukopenia. The remaining 216 patients (98.6%) were found to bear the wild genotype of TPMT (A/A); among them, 79 received AZA, and 18 (22.8%) developed leukopenia. There was no significant difference from those with A/Gs (*P* = 0.071). The frequency of *TPMT* mutation was 1.4%, and *NUDT15* mutation rate was significantly higher and reached 20.1% (*P* = 0.000). Therefore, *NUDT15* gene polymorphism was obviously a better biomarker than *TPMT* gene polymorphism for prediction of AZA-induced leukopenia. Moreover, combined use of corticosteroids reduced the risk of AZA-induced leukopenia (*P* = 0.023, odds ratio (OR) = 0.201, 95% confidence interval (CI): 0.050-0.798, relative risk (RR) = 0.437, preventive fraction (PF) = 0.253) and fewer women than men developed leukopenia after receiving AZA (*P* = 0.039, OR = 0.146, 95%CI: 0.023-0.909, RR = 0.527, PF = 0.124).

Research conclusions
--------------------

In Chinese patients with IBD, the mutation rate of *NUDT15* is significantly higher than that of *TPMT*. *NUDT15* polymorphism is more strongly associated with AZA-induced leukopenia than *TPMT* is. Detecting *NUDT15* genotype before AZA treatment is more effective at predicting the risk of developing leukopenia than detecting *TPMT* genotype. Combined use of corticosteroids is a potential way to reduce the risk of leukopenia. Males have a higher risk of developing AZA-induced leukopenia and need to be more closely monitored than females. Further research is necessary to verify this relationship and determine the precise mechanism.

Research perspectives
---------------------

According to our study, *NUDT15* polymorphism may predict AZA-induced leukopenia more effectively than *TPMT* does. Female sex and corticosteroid usage were negatively associated with developing AZA-induced leukopenia. This might be helpful for AZA-induced leukopenia prevention and to optimize AZA therapy for IBD. While the definite relationship was obscure, more research about how they affect AZA metabolism should be carried out in the future. To learn more about the interaction between them, multicenter studies with larger samples and functional genomics technology may be carried out in future research.

Manuscript source: Unsolicited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

Supported by National Natural Science Foundation of China, No. 81370547 and No. 81400642.

Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Xiangya Hospital, Central South University, Changsha, China.

Clinical trial registration statement: Registration No. ChiCTR-OOC-17010617.

Informed consent statement: Written informed consent was obtained from all the participants.

Conflict-of-interest statement: The authors declare no competing financial interests related to this study.

Peer-review started: December 25, 2017

First decision: January 4, 2018

Article in press: January 18, 2018

P- Reviewer: Gazouli M, Link A, Trifan A S- Editor: Ma YJ L- Editor: Filipodia E- Editor: Ma YJ

[^1]: Author contributions: Wang HH, Yang HX and Tao LJ designed the study; Wang HH, He Y and Wang HX collected the samples; Wang HH, Zhang W and Liao CL performed the DNA extraction and detected the gene polymorphisms; Wang HH, Yang HX, He Y and Wang HX performed follow-up visits; Wang HH, Peng Y, Yang HX and Tao LJ performed the data analysis and interpretation; Wang HH, He Y, Wang HX and Peng Y drafted the manuscript; Yang HX revised the manuscript critically.

    Correspondence to: Hui-Xiang Yang, PhD, Professor, Department of Gastroenterology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan Province, China. <yang_hx430@csu.edu.cn>

    Telephone: +86-731-84327106 Fax: +86-731-88879602
